PMID- 30540994
OWN - NLM
STAT- MEDLINE
DCOM- 20190315
LR  - 20190328
IS  - 1423-0232 (Electronic)
IS  - 0030-2414 (Linking)
VI  - 96
IP  - 3
DP  - 2019
TI  - CpG Island Methylator Phenotype May Predict Poor Overall Survival of Patients
      with Stage IV Colorectal Cancer.
PG  - 156-163
LID - 10.1159/000493387 [doi]
AB  - OBJECTIVE: We aimed to study the prognostic role of CpG island methylator
      phenotype (CIMP) in patients with different stages of colorectal cancer (CRC).
      MATERIAL AND METHODS: We analyzed CIMP in stage I-IV CRC specimens from patients 
      who were diagnosed between 2005 and 2013. CIMP status was determined using a
      5-gene MethyLight-based assay. The clinicopathologic characteristics were
      reviewed and the overall survival (OS) was compared between patients with
      CIMP-high CRC and those with CIMP-low/negative CRC. RESULTS: Among 450 CRC
      specimens with successfully determined CIMP statuses, 74 (16.4%) were CIMP-high
      CRC. Although there was no difference in OS between patients with CIMP-high and
      CIMP-low/negative CRC across all stages (p = 0.4526), intriguingly, patients with
      stage IV CIMP-high CRC had significantly worse OS than those with stage IV
      CIMP-low/negative CRC (p = 0.0047). In a multivariate analysis, CIMP status
      remained an independent prognostic factor for overall mortality (HR = 5.60, 95%
      CI: 2.12-14.79, p = 0.0005) in metastatic CRC after adjusting for
      clinicopathologic variables and anti-cancer therapies. CONCLUSION: Our results
      revealed that the presence of CIMP independently predicts poor OS in patients
      with stage IV CRC.
CI  - (c) 2018 S. Karger AG, Basel.
FAU - Chen, Kuo-Hsing
AU  - Chen KH
AD  - Department of Oncology, National Taiwan University Hospital, Taipei City, Taiwan.
AD  - National Taiwan University Cancer Center, Taipei City, Taiwan.
AD  - Graduate Institute of Oncology, College of Medicine, National Taiwan University, 
      Taipei City, Taiwan.
FAU - Lin, Liang-In
AU  - Lin LI
AD  - Department of Laboratory Medicine, National Taiwan University Hospital, Taipei
      City, Taiwan.
AD  - Department of Clinical Laboratory Sciences and Medical Biotechnology, College of 
      Medicine, National Taiwan University, Taipei City, Taiwan.
FAU - Tseng, Li-Hui
AU  - Tseng LH
AD  - Department of Medical Genetics, National Taiwan University Hospital, Taipei City,
      Taiwan.
FAU - Lin, Yu-Lin
AU  - Lin YL
AD  - Department of Oncology, National Taiwan University Hospital, Taipei City, Taiwan.
AD  - Graduate Institute of Oncology, College of Medicine, National Taiwan University, 
      Taipei City, Taiwan.
FAU - Liau, Jau-Yu
AU  - Liau JY
AD  - Department of Pathology, National Taiwan University Hospital, Taipei City,
      Taiwan.
FAU - Tsai, Jia-Huei
AU  - Tsai JH
AD  - Department of Pathology, National Taiwan University Hospital, Taipei City,
      Taiwan.
FAU - Liang, Jin-Tung
AU  - Liang JT
AD  - Department of Surgery, National Taiwan University Hospital, Taipei City, Taiwan.
FAU - Lin, Been-Ren
AU  - Lin BR
AD  - Department of Surgery, National Taiwan University Hospital, Taipei City, Taiwan.
FAU - Cheng, Ann-Lii
AU  - Cheng AL
AD  - Department of Oncology, National Taiwan University Hospital, Taipei City, Taiwan.
AD  - Department of Internal Medicine, National Taiwan University Hospital, Taipei
      City, Taiwan.
AD  - National Taiwan University Cancer Center, Taipei City, Taiwan.
AD  - Graduate Institute of Oncology, College of Medicine, National Taiwan University, 
      Taipei City, Taiwan.
FAU - Yeh, Kun-Huei
AU  - Yeh KH
AD  - Department of Oncology, National Taiwan University Hospital, Taipei City, Taiwan,
      khyeh@ntu.edu.tw.
AD  - National Taiwan University Cancer Center, Taipei City, Taiwan, khyeh@ntu.edu.tw.
AD  - Graduate Institute of Oncology, College of Medicine, National Taiwan University, 
      Taipei City, Taiwan, khyeh@ntu.edu.tw.
AD  - Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan
      University, Taipei City, Taiwan, khyeh@ntu.edu.tw.
LA  - eng
PT  - Journal Article
DEP - 20181212
PL  - Switzerland
TA  - Oncology
JT  - Oncology
JID - 0135054
RN  - 0 (KRAS protein, human)
RN  - EC 2.7.11.1 (BRAF protein, human)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins B-raf)
RN  - EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))
SB  - IM
MH  - Aged
MH  - Colorectal Neoplasms/*genetics/mortality/pathology
MH  - *CpG Islands
MH  - *DNA Methylation
MH  - Female
MH  - Humans
MH  - Male
MH  - Microsatellite Instability
MH  - Middle Aged
MH  - Mutation
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Proto-Oncogene Proteins B-raf/genetics
MH  - Proto-Oncogene Proteins p21(ras)/genetics
MH  - Survival Rate
OTO - NOTNLM
OT  - CpG island methylator phenotype
OT  - Overall survival
OT  - Stage IV colorectal cancer
EDAT- 2018/12/13 06:00
MHDA- 2019/03/16 06:00
CRDT- 2018/12/13 06:00
PHST- 2018/06/12 00:00 [received]
PHST- 2018/08/29 00:00 [accepted]
PHST- 2018/12/13 06:00 [pubmed]
PHST- 2019/03/16 06:00 [medline]
PHST- 2018/12/13 06:00 [entrez]
AID - 000493387 [pii]
AID - 10.1159/000493387 [doi]
PST - ppublish
SO  - Oncology. 2019;96(3):156-163. doi: 10.1159/000493387. Epub 2018 Dec 12.